複製鏈接
請複製以下鏈接發送給好友
https://baike.baidu.hk/item/梁麗嫺/63211431
複製
複製成功

梁麗嫺

（澳門大學健康科學院教授）

鎖定
梁麗嫺，現任澳門大學健康科學院教授 [1-2]  ，榮獲2020年中醫藥傳承與創新“百千萬”人才工程青年岐黃學者 [1]  。研究方向主要為肺癌靶向治療的中藥新藥研究 [3]  。
中文名
梁麗嫺
畢業院校
香港中文大學 [4] 
學位/學歷
博士 [3] 
職    業
教師
研究方向
肺癌靶向治療的中藥新藥研究 [3] 

目錄

  1. 1 學術成果
  2. 2 所獲榮譽
  3. 3 社會任職
  4. 4 學術論著

梁麗嫺學術成果

研究成果發表在Nature（Outlook），Gut，JAMA Oncology，Pharmacological Research，Pharmacology & Therapeutics，Oncogene，Cancer Letters，British Journal of Cancer等國際重要期刊上已發表SCI論文150餘篇 [1]  [3]  。獲國際發明授權專利39項 [3]  。
長期從事中藥抗腫瘤耐藥研究，取得了系列創新性成果，提出了基於網絡醫學發現中藥活性物質逆轉腫瘤耐藥的新觀點，並發現了克服吉非替尼耐藥的新機制。開展中藥調控糖脂代謝和氧化還原態影響腸道及免疫調節功能進而發揮抗癌作用研究，深入闡釋中藥增敏PD1/PDL1的免疫治療作用抗肺癌的分子機制及其轉化應用價值，完善第三代基因人體菌羣測療與中醫藥療效的關聯分析 [8]  。

梁麗嫺所獲榮譽

研究獲得澳門基金會，澳門科學技術發展基金及中華人民共和國科學技術部與科學技術發展基金聯合科研資助項目等多項資助；獲國家科技部與澳門科技發展基金聯合課題及2018年國家自然科學基金海外及港澳學者合作研究基金 （海外傑青）；獲國家教育部自然科學獎一等獎（排名五），中銀學術研究優秀獎，澳門科學技術自然科學類二等獎等獎勵 [2-3]  。

梁麗嫺社會任職

受邀擔任國際知名藥理學雜誌Pharmacological Research（2022 IF 9.3，醫學1區，Top期刊）主編，是海峽兩岸暨香港、澳門唯一受邀任此職位的學者。同時擔任Antioxidants & Redox Signaling，Engineering及Stem Cell Review and Reports雜誌編委 [1]  。

梁麗嫺學術論著

1. Zhang J, He J, Huang J, Li X, Fan X, Li W, Wu G, Xie C, Fan XX, Zhang J, Yao X, Wang R, Leung EL. Pharmacokinetics, absorption and transport mechanism for ginseng polysaccharides. Biomedicine & Pharmacotherapy. 2023; 162: 114610. (IF=7.5) [5] 
2. Fan XQ, Mai CT, Zuo L, Huang JM, Xie C, Jiang ZB, Li RZ, Yao XJ, Fan XQ, Wu QB, Yan PY, Liu L, Chen JX, Xie Y, Leung EL. Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti inflammatory activity in mice. Acta Pharmaceutica Sinica B. 2022; Available online, In Press. (IF=14.5) [6] 
3. Zhang JM#, Liu P#, Chen J#, Yao D, Liu Q, Zhang J, Zhang HW, Leung EL*, Yao XJ*, Liu L*. Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression. Pharmacological Research. 2022; 187:106565 (IF=9.3) [7] 
4. Xie Y, Feng SL, He F, Yan PY, Yao XJ, Fan XX, Leung EL*, Zhou H*. Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer. Pharmacological Research. 2022; 186: 106514. (IF=9.3)
5. Wang J, Jiang M, Xiong A, Zhang L, Luo L, Liu Y, Liu S, Ran Q, Wu D, Xiong Y, He X, Leung EL*, Li G*. Integrated analysis of single-cell and bulk RNA sequencing reveals pro-fibrotic PLA2G7 macrophages in pulmonary fibrosis. Pharmacological Research. 2022; 182:106286. (IF=9.3)
6. Cai J#, Zhang LC#, Zhao RJ, Pu LM, Chen KY, Nasim AA, Leung EL*, Fan XX*. Chelerythrine ameliorates rheumatoid arthritis by modulating the AMPK/mTOR/ULK-1 signaling pathway. Phytomedicine. 2022; 104:154140. (IF=7.9)
7. Wang XR, Jiang ZB, Xu C, Meng WY, Liu P, Zhang YZ, Xie C, Yu JY, Xie YJ, Liang TL, Yan HX, Fan XX, Yao XJ*, Wu QB* and Leung EL*. Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response. Pharmacological Research. 2022; 179:106198. (IF=9.3)
8. Zhang JM#, Zhang JH#, Liu Q, Fan XX, Leung EL*, Yao XJ*, Liu L*. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacology & Therapeutics. 2022; 229:108050. (IF=13.5)
9. Liang TL#, Li RZ#, Mai CT#, Guan XX, Li JX, Wang XR, Ma LR, Zhang FY, Wang J, He F, Pan HD, Zhou H, Yan PY, Fan XX, Wu QB, Neher E, Liu L, Xie Y*, Leung EL*, Yao XJ*. A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy. Phytomedicine. 2022; 96:153831. (IF=7.9)
10. Zhang FY#, Li RZ#, Xu C#, Fan XX, Li JX, Meng WY, Wang XR, Liang TL, Guan XX, Pan HD, Liu L, Yao XJ, Wu QB* & Leung EL*. Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-Iia. Phytomedicine. 2022; 95:153786. (IF=7.9)
11. Li JX, Li RZ, Sun A, Zhou H, Neher E, Yang JS, Huang JM, Zhang YZ, Jiang ZB, Liang TL, Ma LR, Wang J, Wang XR, Fan XQ, Huang J, Xie Y, Liu L, Tang L, Leung EL, Yan PY. Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. Pharmacological Research. 2021; 171:105574. (IF=9.3)
12. Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR, Zhang YZ, Huang JM, Huang M, Xie C, Liu P, Fan XX, Ma YP, Yan PY, Liu L, Yao XJ, Wu QB, Leung EL. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer letters. 2021; 515:36-48. (IF=9.7)
13. Huang J#, Liu D#, Wang Y#, Liu L, Li J, Yuan J, Jiang Z, Jiang Z, Hsiao WW, Liu H, Khan I, Xie Y, Wu J, Xie Y, Zhang Y, Fu Y, Liao J, Wang W, Lai H, Shi A, Cai J, Luo L, Li R, Yao X, Fan X, Wu Q, Liu Z, Yan P, Lu J, Yang M, Wang L, Cao Y*, Wei H*, Leung EL*. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the anti-tumor effect of anti-programmed cell death 1 /programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut. 2021; 71(4):734-745. (IF=24.5)
14. Jiang ZB, Xu C, Wang W, Zhang YZ, Huang JM, Xie YJ, Wang QQ, Fan XX, Yao XJ, Xie C, Wang XR, Yan PY, Ma YP, Wu QB, Leung EL. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ cells. Pharmacological Research. 2021; 169:105656. (IF=9.3)
15. Song Q, He X, Xiong Y, Wang J, Zhang L, Leung EL*, Li G*. The functional landscape of Golgi membrane protein 1 (GOLM1) phosphoproteome reveal GOLM1 regulating P53 that promotes malignancy. Cell Death Discovry.2021 Mar 01;71(1). (IF=7)
16. Jiang ZB, Huang JM, Xie YJ, Zhang YZ, Chan C, Lai HL, Wang WJ, Yao XJ, Fan XX, Wu QB, Xie C, Wang MF*, Leung EL*. Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. Journal of Experimental & Clinical Cancer Research. 2020; 39:249. (IF=11.3)
17. Leung EL#, Lai HL#, Li RZ, Pan HD, Jiang ZB Li Y, Duan FG, Xu JH, Zhang YZ, Shi AX, Wei CL, Zhang FY, Yao XJ and Liang Liu. Roles of serum amyloid A1 protein isoforms in rheumatoid arthritis. Engineering. 2022; 10:174-182. (IF=12.8)
18. Leung EL*, Xu S*. Traditional Chinese Medicine in Cardiovascular Drug Discovery. Pharmacological Research. 2020; 160:105168. (IF=9.3)
19. Wang WJ, Mao LF, Lai HL, Wang YW, Jiang ZB, Li W, Huang JM, Xie YJ, Xu C, Liu P, Li YM, Leung EL*, Yao XJ*. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway. Pharmacological Research. 2020; 161:105129. (IF=9.3)
20. Liu H, Zheng J, Lai HC, Hu B, Zhu L, Leung EL*, Wei H*. Microbiome technology empowers the development of traditional Chinese medicine. Science China-Life Sciences. 2020; 63(11):1759-61. (IF=9.1)
21. Luo S, Xu J, Jiang Z, Liu L, Wu Q, Leung EL*, Leung AP*. Artificial Intelligence-Based Collaborative Filtering Method with Ensemble Learning for Personalized Lung Cancer Medicine without Genetic Sequencing. Pharmacological Research. 2020; 160:105037. (IF=9.3)
22. Xie YJ, Gao WN, Wu QB, Yao XJ, Jiang ZB, Wang YW, Wang WJ, Li W, Hussain S, Liu L, Leung EL*, Fan XX*. Chelidonine Selectively Inhibits the Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells through the EGFR-AMPK Pathway. Pharmacological Research. 2020; 25:104934. (IF=9.3)
23. Leung EL* & Wu QB*. Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk. JAMA Oncology. 2020; 16(2):385-396. (IF=28.4)
24. Leung EL* & Wu QB*. Commentary on Ge et al. “Insomania and risk of mortality form all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. Sleep Medicine Reviews. 2020; 50:101257. (IF=10.5)
25. Duan FG#, Wang MF#, Cao YB, Dan Li, Li RZ, Fan XX, Khan I, Lai HL, Zhang YZ, Hsiao WW, Yao XJ, Wu QB, Liu L*, Tang YJ*, Leung EL*. MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3'UTR and predicts poor survival in non-small cell lung cancer. Cell Death & Disease. 2019; 10(11):1-4. (IF=9)
26. Wang Y#, Tang C#, Yao S, Lai H, Li R, Xu J, Wang Q, Fan XX, Wu QB, Leung EL*, Ye Y*, Yao X*. Discovery of a novel protein kinase C activator from Croton tiglium for inhibition of non-small cell lung cancer. Phytomedicine. 2019; 65:153100. (IF=7.9)
27. Pan HD#, Xiao Y#, Wang WY, Ren RT, Leung EL* & Liu L*. Traditional Chinese Medicine as a Treatment for Rheumatoid Arthritis-From Empirical Practice to Evidence-based Therapy. Engineering. 2019; 5(5):895-906. (IF=12.8)
28. Xu JH#, Wang QQ#, Leung EL#, Li Y, Fan XX, Wu QB*, Yao XJ* & Liu Liang*. Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin remodeling factor in non-small cell lung cancer. Frontiers of Medicine. 2020; 14(1):60-7. (IF=8.1)
29. Wei CL, Zhang DZ, Cheng JL, Chen X, Fan XX, Xie C, Yao XJ, Wang YW, Jiang ZB, Fu JZ* and Leung EL*. Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. Pharmacological Research. 2019; 144:79-89. (IF=9.3)
30. Leung EL* & Wu QB*. Concurrent use of herbal products with prescription drugs is a double-edged sword and evidence-based medicine contributes to reshaping the practice. Pharmacological Research. 2017; 2:101-7. (IF=9.3)
31. Leung EL#*, Fan XX#, Huang JM#, Huang C, Lin H, Cao YB*. Holistic immunomodulation for small cell lung cancer. Seminars in Cancer Biology. 2022; Available online, In Press. (IF=14.5)
32. Fan XX#, Pan HD#, Li Y, Guo RJ, Leung EL*, Liu L*. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. Pharmacology & therapeutics. 2018; 191:148-61. (IF=13.5)
33. Li RZ#, Fan XX#, Duan FG, Jiang ZB, Pan HD, Luo LX, Zhou YL, Li Y, Yao YJ, Leung EL* & Liu L*. Proscillaridin A induces apoptosis and suppresses non-small cell lung cancer tumor growth via calcium-induced DR4 up-regulation. Cell Death & Disease. 2018; 9(6):1-4. (IF=9)
34. Leung EL#, Luo LX#, Liu ZQ, Wong VKW, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ*, Ward DC*, Liu L*. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell Death & Disease. 2018; 9(2):1-5. (IF=9)
35. Leung EL, Clementi E, Wong WS. Advanced technologies charting a new path for traditional Chinese medicine drug discovery. Pharmacological Research. 2017; 117:65. (IF=9.3)
36. Li X#, Fan XX#, Jiang ZB, Loo WTY, Yao XJ, Leung EL*, Chow LWC*, Liu L*. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway. Pharmacological Research. 2017; 115:45-55. (IF=9.3)
37. Wong VK#, Law YK#, Yao XJ, Chen X, Xu SW, Liu L*, Leung EL*. Advanced research technology for discovery of new effective compounds from Chinese herbal medicine and their molecular targets. Pharmacological Research. 2016; 111:546-55. (IF=9.3)
38. Yang ZF#, Leung EL#, Liu L, ZH Jiang, Zhong NS*. Developing influenza treatments using traditional Chinese medicine. Science. 2015; 347(6219):S35-7. (IF=56.9) [2] 
參考資料